Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if ...

Google Cloud's updated its Vertex AI platform to support AI agents with including the Agent Development Kit, the Agent2Agent ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $492.69, indicating a -1.96% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily ...

As previously reported, Cantor Fitzgerald assumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and a price target of ...

BNP Paribas Exane initiated coverage of Vertex (VERX) with an Outperform rating and $54 price target Stay Ahead of the Market: Discover ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $51.3, a high estimate of $61.00, and a low estimate of $31.00. A 14.64% drop is evident in the current ...

For the full year 2025, Vertex (NASDAQ:VRTX) projects revenue to be in the range of $11.75 billion to $12 billion. In recent developments, Vertex announced that the United Kingdom Medicines and ...

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. One of these two impactful publications was issued by Swiss bank UBS analyst Eliana Merle. The second of the pair ...

Vertex Pharmaceuticals is strutting toward its Q1 earnings report with a 22.3% stock surge this year, brushing up against its 52-week high. While analysts expect a dip in earnings per share, revenue ...